Norman Greenberg tests AstraZeneca compounds on mice he genetically engineered to develop prostate cancer. He supplies the animals and the system for verifying the effectiveness of chemotherapy treatments while the company provides the compounds and testing costs, and gives Greenberg ample opportunity to prove just how well his system works.

Together, the scientist from Baylor College of Medicine in Houston and his corporate partner warily straddle the barrier between academia and industry, and in the process, develop new treatments that may someday save lives. "Our situation with AstraZeneca is very focused on a number of targets, discrete compounds, and what they do in a specific system," says Greenberg, an associate professor of molecular and cellular biology. "It really helps us in the long run because we're going to make better models, we're going to know more about them, and how to use them. AstraZeneca benefits too, because they learn more...

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?